K-Ras G12C-IN-2

• CAT Number: I002112
• CAS Number: 1629267-75-9
• Molecular Formula: C21H27ClN4O3
• Molecular Weight: 418.92
• Purity: ≥95%
• Synonyms: 1-(3-(4-(2-((4-chloro-5-cyclopropyl-2-hydroxyphenyl)amino)acetyl)piperazin-1-yl)azetidin-1-yl)prop-2-en-1-one
• Target: MAPK/ERK Pathway
• Solubility: DMSO: ≥ 22 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 1-[3-[4-[2-(4-chloro-5-cyclopropyl-2-hydroxyanilino)acetyl]piperazin-1-yl]azetidin-1-yl]prop-2-en-1-one
• InChI: InChI=1S/C21H27ClN4O3/c1-2-20(28)26-12-15(13-26)24-5-7-25(8-6-24)21(29)11-23-18-9-16(14-3-4-14)17(22)10-19(18)27/h2,9-10,14-15,23,27H,1,3-8,11-13H2
• InChIKey: LTHUJAPYGTUVMD-UHFFFAOYSA-N
• SMILES: C=CC(=O)N1CC(C1)N2CCN(CC2)C(=O)CNC3=C(C=C(C(=C3)C4CC4)Cl)O

K-Ras G12C-IN-2 (Cat No.: I002112) is an emerging small molecule inhibitor specifically designed to target the oncogenic K-Ras G12C mutation found in certain cancers, such as non-small cell lung cancer. The compound covalently binds to the mutated cysteine residue, effectively locking the protein in its inactive GDP-bound conformation. By disrupting downstream signaling pathways, including MAPK and PI3K, it impedes tumor proliferation. Preliminary preclinical findings indicate notable improved potency and selectivity. Ongoing studies aim to confirm safety, efficacy, and pharmacokinetics for future clinical use.